Healthcare >> Analyst Interviews >> September 20, 2004
DR. YARON WERBER is senior analyst covering the biotechnology sector at
Smith Barney. Mr. Werber joined Smith Barney from SG Cowen Securities
were he was a senior analyst and member of the research team that was
ranked number one for small and mid-cap coverage by the Greenwich Survey
in 2002. In 2003, Dr. Werber was ranked among the top five analysts in
the biotech sector by the 'Best on the Street Survey' of the Wall Street
Journal. Previously, Dr. Werber was a consultant in the biomedical arena
with clients including New England Medical Center, ImClone Systems and
EmMax, a pharmaceutical marketing firm, where he worked on projects for
Pfizer. Before becoming a consultant, Mr. Werber was Director of
Strategic Business Development at NotifyMD, a privately held e-health
company. He began his career as a Research Associate and Business
Analyst at New England Medical Center, Boston. Dr. Werber received a BS
in biology, and a combined MD/MBA from Tufts University. Profile
Dr. Werber: In my first tranche, I initiated coverage of ImClone Systems
(IMCL), Millennium Pharmaceuticals (MLNM),
